Vertex Pharmaceuticals Incorporated (VRTX:NASDAQ) closed at $539.77 on November 13, 2026, down 0.53% on the day. The stock trades 5.1% below its 52-week high of $568.67 and 30.9% above its 52-week low of $412.27. Over the past year, it gained 24.9%. Vertex Pharmaceuticals Incorporated is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 12, 2025, VRTX closed higher on 126 days (50%). Its best day was March 10, 2026 (+8.31%) and its worst was July 8, 2026 (-4.56%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 1 time.
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early...
Find more stocks like VRTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.